Abstract
Despite surgical and technological progress in the treatment of neurological diseases over the past 50 years, advances regarding to the treatment of malignant brain tumors (BTs) have not kept abreast. Malignant astrocytoma is the most frequent primary BT in adults, and accounts for 2% of all cancers in this population (1). The incidence of malignant astrocytoma varies considerably with age. For glioblastoma multiforme (GBM), it ranges from 0.2/100,000 population in the under 14 yr age group to 4.5/100,000 population in the over 45 yr age group. There is a similar but less dramatic increase in the incidence of ana-plastic astrocytoma (AA) with age, ranging from 0.5 to 1.7/100,000 population between the same age groups (2). This steady rise in the incidence of malignant astrocytoma, initially thought to peak in the 55-60-yr-old age group, has more recently been shown to continue to increase into the eighth decade of life (3,4). The average annual increase in the incidence of primary BTs in elderly patients in the United States, between 1974 and 1985, was 7.0% for the 75-79-yr-old age group, 20.4% in the 80–84 yr age group, and 23.4% in those 85 yr and older. These diagnoses were predominantly GBM and AA (4). The precise reason for this rise is uncertain. It may result from either the increased availability of computed tomography and magnetic resonance imaging (MRI) or, as suggested in one study (5), a true independent increase in incidence. Overall, there is a slight male predominance with both GBM and AA (3,6–9). With the incidence of malignant gliomas starting to increase in the fifth decade (7), this fatal disease inflicts an enormous social and economic impact, often striking during the most productive period in a patient’s life.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Salcman, M. (1995) Glioblastoma and malignant astrocytoma, in Brain Tumors ( Kaye, A. H., Laws, Jr., E. R., eds.), Churchill Livingstone, New York, pp. 449–477.
Cohen, A. and Modan, B. (1968) Some epidemiologic aspects of neoplastic diseases in Israeli immigrant population. III. Brain tumors. Cancer 22, 1323–1328.
Mao, Y., Desmeules, M. R., Semenciw, R. M., Hill, G., Gaudette, L., et. al. (1991) Increasing brain cancer rates in Canada. Can. Med. Assoc. J. 145, 1583–1591.
Greig, N. H., Ries, L. G. Yancik, R., and Rapoport, S. I. (1990) Increasing annual incidence of primary malignant brain tumors in the elderly. J. Natl. Cancer Inst. 82, 1594–1596.
Desmeules, M., Mikkelsen, T., and Mao, Y. (1992) Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. J. Natl. Cancer Inst. 84, 442–445.
Annegers, J. F., Schoenberg, B. S., Okazaki, H., and Kurland, L. T. (1981) Epidemiologic study of primary intracranial neoplasms. Arch. Neurol. 38, 217–219.
Barker, D. J. P., Weller, R. O., and Garfield, J. S. (1976) Epidemiology of primary tumours of the brain and spinal cord: a regional survey in southern England. J. Neurol. Neurosurg. Psychiatry 39, 290–296.
Kurland, L. T., Schoenberg, B. S., Annegers, J. F., Okasaki, H., and Molgaard, C. A. (1982) The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935–1977. Ann. NYAcad. Sci. 381, 6–16.
Trouillas, P., Menaud, G., DeThe, G., Aimard, G., and Devic, M. (1975) Etude epidemiologique des tumeurs primitives du nevraxe dans la Rhones-Alpes. Donnees quantitatives relatives a 1’etiologie et a la repartition geographique de 1670 tumeurs. Rev. Neurol. 131, 691–708.
Ebeling, U. and Hasdemir, M. G. (1995) Stereotactic guided microsurgery of cerebral lesions. Min. Invasive Neurosurg. 38, 10–15.
Ojemann, J. G., Miller, J. W., and Silbergeld, D. L. (1996) Preserved function in brain invaded by tumor. Neurosurgery 39, 253–258.
Ebeling, U. and Reulen, H.-J. (1995) Space-occupying lesions of the sensorimotor region. Adv. Tech. Stand. Neurosurg. 22, 137–181.
Ebeling, U., Fischer, M., and Kothbauer, K. (1995) Surgery of astrocytomas in the motor and premotor cortex under local anesthesia: report of 11 cases. Min. Invasive Neurosurg. 38, 51–59.
Bennett, H. and Godlee, R. J. (1884) Excision of a tumour from the brain. Lancet 2, 1090–1091.
Nazzaro, J. M. and Neuwelt, E. A. (1990) The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J. Neurosurg. 73, 331–344.
Scheibel, R. S., Meyers, C. A., and Levin, V. A. (1996) Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J. Neuro-oncol. 30, 61–69.
Silbergeld, D. L. and Chicoine, M. R. (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J. Neurosurg. 86, 525–531.
Harbaugh, K. S. and Black, P. M. (1998) Strategies in the surgical management of malignant gliomas. Semin. Surg. Oncol. 14, 26–33.
Salcman, M. (1985) Supratentorial gliomas: Clinical features and surgical therapy, in Neurosurgery ( Wilkins, R. H. and Rengachary, S. S., eds.), McGraw-Hill, New York, pp. 550–579.
Fernandez, P. M. and Brem, S. (1997) Malignant brain tumors in the elderly. Clin. Geriatr. Med. 13, 327–338.
Hirakawa, K., Suzuki, K., Ueda, S., et al. (1984) Multivariate analysis of factors affecting postoperative survival in malignant astrocytoma. J. Neuro-oncol. 2, 331–340.
Ciric, I., Ammirati, M., Vick, N., and Mikhael, M. (1987) Supratentorial gliomas: surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 21, 21–26.
Andreou, J., George, A. E., Wise, A., et. al. (1983) Chemotherapy prognostic criteria of survival after malignant glioma surgery. Am. J. Neuroradiol. 4, 488–490.
Ammirati, M., Vick, N., Liao, Y., et al. (1987) Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21, 201–206.
Nitta, T. and Sato, K. (1995) Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75, 2727–2731.
Albert, F. K., Forsting, M., Sartor, K., Adams, H. P., and Kunze, S. (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34, 45–60.
Wood, J. R., Greene, S. B., and Shapiro, W. R. (1988) The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J. Clin. Oncol. 6, 338–343.
Devaux, B. C., O’Fallon, J. R., and Kelly, P. J. (1993) Resection, biopsy and survival in malignant glial neoplasms: a retrospective study of clinical parameters, therapy and outcome. J. Neurosurg. 78, 767–775.
Barker, F. G., Chang, S. M., Gutin, P. H., et al. (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42, 709–723.
Karnofsky, D., Abelman, W., Craver, L., et al. (1949) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1, 634.
Harsh IV, G. R., Levin, V. A., Gutin, P. H., et al. (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21, 615–621.
Salcman, M., Kaplan, R. S., Ducker, T. B., Abdo, H., and Montgomery, E. (1982) Effect of age and reoperation on survival in the multimodality treatment of malignant astrocytoma. Neurosurgery 73, 331–344.
Ammirati, M., Galicich, J. H., Arbit, E., et al. (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21, 601–614.
Kelly, P. J. and Hunt, C. (1994) The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 34, 62–66.
Halperin, E. C. (1995) Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. Oncology 9, 229–234.
Andersen, A. P. (1978) Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol. Oncol. 17, 475–484.
Walker, M. D., Alexander Jr., E., Hunt, W. E., et al. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J. Neurosurg. 49, 333–343.
Walker, M. D., Green, S. B., Byar, D. P., et al. (1980) Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323–1329.
Salcman, M. (1980) Survival in glioblastoma: historical perspective. Neurosurgery 7, 435–439.
Walker, M. D., Strike, T. A., and Sheline, G. E. (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 5, 1725–1731.
Chang, C. H., Horton, J., Schoenfeld, D., et al. (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52, 997–1007.
Wood, J. R., Greene, S. B., and Shapiro, W. R. (1988) The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J. Clin. Oncol. 6, 338–343.
Hoffman, W. F., Levin, V. A., and Wilson, C. B. (1979) Evaluation of malignant glioma patients during the post-irradiation period. J. Neurosurg. 50, 624–628.
Sheline, G. E., Wara, W. M., and Smith, V. (1980) Therapeutic irradiation and brain injury. Int. J. Radiat. Oncol. Biol. Phys. 6, 1215–1228.
Leibel, S. A., Gutin, P. H., Wara, W. M., et al. (1989) Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 17, 1129–1139.
Salcman, M. Intrinsic cerebral glioma, in Brain Surgery, vol. 1 (Apuzzo, M. L. J., ed.), Churchill Livingstone, New York, pp. 379–390.
Florell, R. C., MacDonald, D. R., Irish, W. D., et al. (1992) Selection bias, survival, and brachytherapy for glioma. J. Neurosurg. 76, 179–183.
Ryken, T. C., Hitchon, P. W., Van Gilder, J. C., Wen, B. C., and Jani, S. (1994) Interstitial brachytherapy versus cytoreductive surgery in recurrent malignant glioma. Stereotactic Funct. Neurosurg. 63, 241–245.
Petersdorf, S. H. and Berger, M. S. (1996) The molecular basis of neurosurgical disease, in Concepts in Neurosurgery, vol. 8 (Raffel, C. and Harsh IV, G. R., eds.), Williams and Wilkins, Baltimore, MD, pp. 198–210.
Hosli, P., Sappino, A. P., de Tribolet, N., and Dietrich, P. Y. (1998) Malignant glioma: Should chemotherapy be overthrown by experimental treatments? Ann. Oncol. 9, 589–600.
Levin, V. A., Gutin, P. H., and Leibel, S. (1993) Neoplasms of the Central Nervous System, in Cancer. Principles and Practice of Oncology ( De Vita, Jr., V. T., Hellman, S., and Rosenberg, S. A., eds.), Lippincott, Philadelphia, pp. 1679–1737.
Smart, C. R., Ottoman, R. E., and Rochlin, D. B. (1968) Clinical experience with vincristine in tumors of the central nervous system and other malignant diseases. Cancer Chem. Rep. 52, 733–741.
Newlands, E. S., O’Reilly, S. M., and Glaser, M. G. (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 32A, 2236–2241.
Levin, V. A. and Prados, M. (1999) Phase II study of Temodal (Temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. J. Clin. Oncol. 17, 2762–2771.
Levin, V. A., Edwards, M. S., and Wright, D. C. (1980) Modified procarbazine, CCNU and vincristine (PCV3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat. Rep. 64, 237–241.
Coyle, T., Baptista, J., and Winfield, J. (1990) Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: A phase II study. J. Clin. Oncol. 8, 2014–2018.
Longee, D. C., Friedman, H. S., and Albright, R. E. (1990) Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J. Neurosurg. 72, 583–588.
Levin, V. A. and Prados, M. D. (1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosurea resistance. J. Clin. Oncol. 10, 766–771.
Rajan, B., Ross, G., and Lim, C. C. (1994) Survival in patients with recurrence as a measure of treatment efficacy: prognostic factors following nitrosurea chemotherapy. Eur. J. Cancer 30A, 1809–1815.
Hildebrand, J., Sahmoud, T., and Mignolet, F. (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44, 1479–1483.
Levin, V. A., Silver, P. B. A., and Hannigan, J. M. S. (1990) Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18, 321–324.
Fine, H. A., Dear, K. B. G., and Loeffler, J. S. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585–2597.
Cairncross, G., MacDonald, D., and Ludwin, S. (1994) Chemotherapy for anaplastic oligodendroglioma. J. Clin. Oncol. 12, 2013–2021.
Cairncross, G., Swinnen, L., and Stiff, P. (1997) High-dose thiotepa with hematopoietic reconstitution (deferring radiation) for newly diagnosed aggressive oligodendroglioma. Proc. Am. Soc. Clin. Oncol. 16, 388.
Hochberg, F. H. and Pruitt, A. (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30, 907–911.
Walter, K. A., Tamargo, R. J., and Olivi, A. (1995) Intratumoral chemotherapy. Neurosurgery 37, 1129–1145.
Brem, H., Mahaley, M. S., and Vick, N. A. (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74, 441–446.
Brem, H., Piantadosi, S., and Burger, P. C. (1995) Placebo controlled trial of safety and efficacy of intraopertaive controlled delivery by biodgradable polymers of chemotherapy for recurrent gliomas. Lancet 345, 1008–1012.
Kim, K. J., Li, B., Winer, J., et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841–844.
Bailar, J. C. and Gornik, H. L. (1997) Cancer undefeated. N. Engl. J. Med. 336, 1569–1574.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Duff, J.M., Dietrich, PY., de Tribolet, N. (2001). Current Therapy for Primary Brain Tumors. In: Liau, L.M., Becker, D.P., Cloughesy, T.F., Bigner, D.D. (eds) Brain Tumor Immunotherapy. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-035-3_3
Download citation
DOI: https://doi.org/10.1007/978-1-59259-035-3_3
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-110-3
Online ISBN: 978-1-59259-035-3
eBook Packages: Springer Book Archive